InvestorPlace

Buy SAVA Stock on Dips as its Phase 3 Trial Moves Along

Is the recent pullback in Cassava Sciences (NASDAQ:SAVA) a sign that it’s time to give up on this risky biotech play? Or, is it an opportunity to enter and/or add to a position in SAVA stock, at a more favorable price? Source: Pavel Kapysh / Shutterstock.com I would say the latter. Yes, this is a very speculative stock. If it fails to make further progress with its Alzheimer’s treatment, Simulfilam? Shares could see a tremendous drop in price. But a year or so down the road, once the data from i

LEAVE A REPLY

Please enter your comment!
Please enter your name here